The unexpected finding of pre-existing T-cell reactivity to the AstraZeneca and Janssen vaccines may explain why some people rarely developed thrombotic thrombocytopenia syndrome after vaccination.
The unexpected finding of pre-existing T-cell reactivity to the AstraZeneca and Janssen vaccines may explain why some people rarely developed thrombotic thrombocytopenia syndrome after vaccination.
Read More
The revision states that the vaccine can cause thrombosis with thrombocytopenia syndrome, which may be life-threatening.
Read More
The FDA limited authorized use of the J&J Janssen COVID-19 vaccine to certain individuals due to risk of thrombosis with thrombocytopenia syndrome.
Read More
Once approved, Johnson & Johnson expects to supply 100 million doses of its COVID-19 vaccine to the US in the first half of 2021.
Read More
